In 30% of AML patients, nucleophosmin 1 (NPM1) frameshift mutations yield a de novo nuclear export signal that retargets this chaperone from the nucleolus to the cytoplasm (Falini et al., 2020). This evidence concerns the gene NPM1 and acute myeloid leukemia.